Relmada Therapeutics to Present at 11th Annual Noble Financial Capital Markets Equity Conference
Presentation on January 20, 2015 at 4:00 PM Eastern Time.
NEW YORK, Jan. 16, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will provide a business overview and update at the Noble Financial Capital Markets Equity Conference being held on January 18-21, 2015 in Sandpiper Bay, Florida.
Michael Becker, Senior Vice President of Finance and Corporate Development at Relmada Therapeutics, will present on Tuesday, January 20 at 4:00 p.m. Eastern time, with one-on-one meetings held throughout the conference event.
Members of the investment community who are interested in meeting with management should contact Christine Silverstein, Director of Investor Relations at Relmada Therapeutics, at (212) 702-7167 or [email protected]
At the time of the presentation, a live audio and high-definition video webcast of Relmada's presentation will be available on the Company's web site www.relmada.com, or through the Noble Financial websites: www.noblefcm.com, or www.nobleresearch.com/D2/2015.htm. Relmada recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast and presentation will also be archived for 90 days following the event.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; d-Methadone, its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; BuTab ER, its oral dosage form of the opioid analgesic buprenorphine; and MepiGel, its orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at: www.relmada.com.
About Noble Financial
Noble Financial Capital Markets was established in 1984. Noble Financial is an equity research driven, full-service, investment banking boutique focused on life sciences, technology, energy and media, emerging growth, companies. The company has offices in New York, Boston, Los Angeles, and Boca Raton, FL. In addition to non-deal road shows and sector-specific conferences throughout the year, Noble Financial hosts its large format annual equity conference in January in South Florida featuring 120 - 150 presenting companies from across North America and total attendance of close to 600. For more information: www.noblefcm.com
Forward-Looking Statements
This news release contains "forward-looking statements." These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Contact
Investor Contact:
Michael Becker, SVP of Finance and Corporate Development
Relmada Therapeutics, Inc.
Tel: 212-702-7169
[email protected]
Media Contact:
Bill Berry
Berry & Company Public Relations
Tel: 212-253-8881
[email protected]
Logo - http://photos.prnewswire.com/prnh/20150113/168770LOGO
SOURCE Relmada Therapeutics, Inc.
Share this article